In another phase II basket trial (NCI-MATCH) of tumors including breast, urothelial, and cervical cancers harboring FGFR1-3 aberrations, fexagratinib did not meet its primary endpoint and demonstrated ORR of only 8% (90% CI: 3–18%) with responses observed only in patients with FGFR1-3 point mutations or fusions. This evidence concerns the gene FGFR1 and cervical cancer.